ArticleCancer immunology research2023

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies.

Beatriz Aranda-Orgilles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.